# Evommune, Inc. (EVMN) · Edgar & Edgarette company card

> Evommune (EVMN) grew revenue 85.7% in FY2025 to $13 million, operating margin -624% against a -3.8% median for pharmaceutical preparations, equity 91.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 2044725 · fiscal year ended 2025-12-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/EVMN) · [JSON](https://www.pops4.com/boards/company/EVMN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $13M |
| Revenue growth, 1 year | 85.7% |
| Revenue growth per year | — |
| Operating margin | -623.6% (prior year -1000.2%) |
| Net margin | -529.8% |
| Operating cash flow | −$76M |
| Capital spending | $235,000 |
| Free cash flow | −$77M |
| Cash | $44M |
| Long-term debt | — |
| Total assets | $225M |
| Total equity | $206M |
| Equity ÷ assets | 91.4% |
| Return on equity | -33.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 9.47 (safe zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -623.6% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $13.0M (FY2025). Experience: revenue up 85.7% on the year; operating margin -623.6%, up from -1000.2%. Soundness: equity 91.4% of assets, return on equity -33.5%. Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $17.7M and $31.8M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -623.6% against a -3.8% median; growth 85.7% against 13.7%.

Range logged 2026-09-20, receipt bbe5ce7011aff7fc, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-10-01 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2044725/000119312526409865/0001193125-26-409865-index.htm)
- 8-K · filed 2026-09-23 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2044725/000119312526399378/0001193125-26-399378-index.htm)
- 8-K · filed 2026-09-15 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2044725/000119312526391390/0001193125-26-391390-index.htm)
- 8-K · filed 2026-09-09 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2044725/000119312526385430/0001193125-26-385430-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/2044725/000119312526337984/0001193125-26-337984-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2044725/000119312526337964/0001193125-26-337964-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0002044725.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2044725

## Cite

POPS4, Edgar & Edgarette: Evommune, Inc. (EVMN) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/EVMN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.